Overview

Study of Pharmacokinetics, Efficacy and Safety of a Recombinant and Protein-Free Factor VIII (rAHF-PFM) in Hemophilia A Patients - A Continuation of Clinical Study 069901

Status:
Completed

Trial end date:
2004-08-03

Target enrollment:

Participant gender:

Summary

The purpose of this study is to evaluate whether rAHF-PFM is safe and effective in the treatment of hemophilia A subjects. The study consists of 2 parts: Part 1 is a pharmacokinetic and safety study, and Part 2 is an evaluation of efficacy and safety. The study is open to patients who completed Baxter Study 069901.

Phase:

Phase 2/Phase 3

Details

Lead Sponsor:

Baxalta now part of Shire
Baxalta US Inc.

Treatments:

Factor VIII